---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-001162"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T19:36:04.864333+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Relmada Therapeutics engages director Paul Kelly as special advisor at $32k/mo; Kelly loses independent director status

## Summary
- Paul Kelly, a director, entered Advisory Agreement as Special Advisor to CEO effective Jan 1, 2023, with $32,000 monthly fee.
- Kelly will no longer be considered independent director; he resigns from Audit and Compensation Committees.
- Charles J. Casamento appointed Chairman of Compensation Committee effective Jan 1, 2023.
- Agreement term of one year, renewable automatically; early termination with 30 days' notice.

## SEC filing metadata
- accession: 0001213900-23-001162
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390023001162/0001213900-23-001162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390023001162/ea171314-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-001162
- JSON: https://secwatch.observer/filing/0001213900-23-001162.json
- Plain text: https://secwatch.observer/filing/0001213900-23-001162.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.